article thumbnail

First Ever Investigational 18F-CD8 PET Radiopharmaceutical Aims to Predict and Monitor Early Response to Cancer Immunotherapies

Imaging Technology

The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use.

article thumbnail

SOFIE and GE HealthCare Enter Licensing Agreement to Develop FAP PET Radiotracers

Imaging Technology

milla1cf Wed, 10/11/2023 - 13:24 October 11, 2023 — GE HealthCare today announced an exclusive global licensing agreement with SOFIE Biosciences (SOFIE), a Virginia, U.S.-based SOFIE and GE HealthCare will collaborate on both the development and commercialization processes through a joint steering committee. Sherly Mosessian , Ph.D,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

GE HealthCare Closes MIM Software Acquisition

Imaging Technology

milla1cf Tue, 04/02/2024 - 18:51 April 2, 2024 — Less than three months after signing an agreement to acquire MIM Software Inc. , GE HealthCare Technologies Inc. This includes continuing to grow MIM Software’s offerings for end-to-end standardization across large healthcare system fleets.

article thumbnail

GE HealthCare Announces New Data Validating Artificial Intelligence Models for Predicting Patient Response to Immunotherapies

Imaging Technology

milla1cf Thu, 11/02/2023 - 13:52 November 2, 2023 — GE HealthCare’s Artificial Intelligence ( AI ) models predict patient response to immunotherapies with 70 to 80 percent accuracy [1] , based on a pan-cancer cohort, according to findings to be presented at the Society for Immunotherapy of Cancer ( SITC ) in San Diego, U.S.,

article thumbnail

NorthStar Medical Radioisotopes Announces Promotion of Jason Vinyard, MBA, MHA, to Vice President, Business Development, Therapeutic Technologies

Imaging Technology

He has more than 22 years of operational and commercial expertise in radioisotopes and radiopharmaceuticals. actinium-225 (Ac-225), and drive business development initiatives for NorthStar’s Radiopharmaceutical CDMO/CMO business units. Ac-225 and Cu-67 using environmentally preferable technologies. Francis in Joliet, Ill.,

article thumbnail

NorthStar Medical Radioisotopes Expands Management Team with Appointment of Jean-Noel David, MBA, MS, as Vice President, Operations

Imaging Technology

milla1cf Mon, 04/24/2023 - 14:10 April 24, 2023 — - NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, has announced the appointment of Jean-Noel David , MBA, MS, as Vice President, Operations.

Medical 81
article thumbnail

ITM and CNL Announce the Launch of Actineer, a New Joint Venture in the Global Production of Actinium-225

Imaging Technology

CNL will provide the starting material for irradiation and initially manage the production process during the interim scale of radiochemical grade 225Ac supply, while ITM will further process the resulting 225Ac to pharmaceutical grade under Good Manufacturing Process (GMP) specifications. Lutetium-177.